Subtype-Specific Aptamer Technologies for Breast Cancer: From Molecular Recognition to Precision Applications
Biosensors · 2026
DOI: 10.3390/bios16100549 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biosensors, 2026. Verfasst von Huibin Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Pharmaceutical Analysis and Medicine of Fujian Province, School of Pharmacy and Medical Technology, Putian University, Putian 35110…. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Biosensing Techniques, Breast Neoplasms. Die Arbeit nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Fujian Province, Startup Fund for Advanced Talents of Putian University, Qinghai Provincial Science Foundation.
Abstract (Originalsprache)
Breast-cancer management depends on reproducible molecular classification, yet tissue-based assays provide only spatially and temporally restricted views of a heterogeneous disease. Aptamers are programmable single-stranded DNA or RNA ligands that can integrate molecular recognition with biosensing, liquid-biopsy capture and targeted delivery. This review follows the translational chain from aptamer selection and molecular recognition to subtype resolution, signal or cargo conversion, biological validation, and clinical translation. We compare HER2-directed aptamers, ERα- and PHB2-associated tools for hormone-receptor-positive disease, and phenotype-oriented ligands for triple-negative breast cancer. We further organize aptasensors by signal-conversion mechanism, distinguish analytical performance in buffer from that in clinical matrices, and clarify the complementary role of aptamers in liquid-biopsy workflows, including CTC and extracellular-vesicle enrichment alongside separate ctDNA sequence-variant analysis. For theranostic systems, affinity alone is insufficient; pharmacokinetics, receptor trafficking, endosomal escape and comparator-controlled efficacy ultimately determine functional benefit. Aptamers are therefore most compelling as modular recognition elements for multiplexing, reversible engineering, and targeted delivery. Progress will depend on transparent selection reporting, orthogonal target validation, and prospective multicenter studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Pharmaceutical Analysis and Medicine of Fujian Province, School of Pharmacy and Medical Technology, Putian University, Putian 351100, China.
- College of Biological and Food Engineering, Hubei MinZu University, Enshi 445000, China.
Förderung
- Natural Science Foundation of Fujian Province
- Startup Fund for Advanced Talents of Putian University
- Qinghai Provincial Science Foundation
Zitieren
APA
Wu, H., Zeng, Z., Huang, W., Lin, X., Tian, R., Chen, J., & Zhang, Q. (2026). Subtype-Specific Aptamer Technologies for Breast Cancer: From Molecular Recognition to Precision Applications. Biosensors. https://doi.org/10.3390/bios16100549
Vancouver
Wu H, Zeng Z, Huang W, Lin X, Tian R, Chen J, et al. Subtype-Specific Aptamer Technologies for Breast Cancer: From Molecular Recognition to Precision Applications. Biosensors. 2026. doi:10.3390/bios16100549
BibTeX
@article{Wu2026,
author = {Wu, Huibin and Zeng, Zhi and Huang, Wenyi and Lin, Xinyan and Tian, Rui and Chen, Jianmin and Zhang, Qiulong},
title = {Subtype-Specific Aptamer Technologies for Breast Cancer: From Molecular Recognition to Precision Applications},
journal = {Biosensors},
year = {2026},
doi = {10.3390/bios16100549}
}
EUVIMED